Advertisement
Screener

REPLIMUNE GROUP, INC. (REPL) Interest Expense on Debt

2.8 / 5 stars · 68/120 Roast Me

REPLIMUNE GROUP, INC. Interest Expense on Debt

REPLIMUNE GROUP, INC. (REPL) reported Interest Expense on Debt of $2.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Expense Statement › Interest Expense

us-gaap:InterestExpenseDebt · last filed 2026-08-14

  • REPLIMUNE GROUP, INC. interest expense, debt for the quarter ending 2026-06-30 was $2.58M, a 74.98% increase year-over-year.
  • REPLIMUNE GROUP, INC. interest expense, debt for the quarter ending 2026-03-31 was $2.37M, a 62.01% increase year-over-year.
  • REPLIMUNE GROUP, INC. interest expense, debt for the quarter ending 2025-12-31 was $1.47M, a 1.10% increase year-over-year.
  • REPLIMUNE GROUP, INC. interest expense, debt for the quarter ending 2025-09-30 was $1.49M, a 3.48% increase year-over-year.
  • REPLIMUNE GROUP, INC. interest expense, debt for fiscal 2026 was $6.80M, a 17.68% increase from fiscal 2025.
  • REPLIMUNE GROUP, INC. interest expense, debt for fiscal 2025 was $5.78M, a 28.42% increase from fiscal 2024.
  • REPLIMUNE GROUP, INC. interest expense, debt for fiscal 2024 was $4.50M, a 129.09% increase from fiscal 2023.
  • REPLIMUNE GROUP, INC. interest expense, debt for fiscal 2023 was $1.96M.
Period endInterest Expense, Debt 3 monthInterest Expense, Debt 6 monthInterest Expense, Debt 9 monthInterest Expense, Debt 12 month
2026-06-30$2.58M
10-Q · filed 2026-08-14
$4.95M
derived: sum of 2 quarters · filed 2026-08-14
$6.41M
derived: sum of 3 quarters · filed 2026-08-14
$7.90M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$2.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29
$3.83M
derived: sum of 2 quarters · filed 2026-06-29
$5.32M
derived: sum of 3 quarters · filed 2026-06-29
$6.80M
10-K · filed 2026-06-29
2025-12-31$1.47M
10-Q · filed 2026-02-03
$2.95M
derived: sum of 2 quarters · filed 2026-02-03
$4.43M
10-Q · filed 2026-02-03
$5.89M
derived: sum of 4 quarters · filed 2026-08-14
2025-09-30$1.49M
10-Q · filed 2025-11-06
$2.96M
10-Q · filed 2025-11-06
$4.42M
derived: sum of 3 quarters · filed 2026-08-14
$5.87M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30$1.48M
10-Q · filed 2026-08-14
$2.94M
derived: sum of 2 quarters · filed 2026-08-14
$4.39M
derived: sum of 3 quarters · filed 2026-08-14
$5.82M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31$1.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29
$2.91M
derived: sum of 2 quarters · filed 2026-06-29
$4.35M
derived: sum of 3 quarters · filed 2026-06-29
$5.78M
10-K · filed 2026-06-29
2024-12-31$1.45M
10-Q · filed 2026-02-03
$2.89M
derived: sum of 2 quarters · filed 2026-02-03
$4.31M
10-Q · filed 2026-02-03
$5.73M
derived: sum of 4 quarters · filed 2026-02-03
2024-09-30$1.44M
10-Q · filed 2025-11-06
$2.86M
10-Q · filed 2025-11-06
$4.28M
derived: sum of 3 quarters · filed 2025-11-06
$5.29M
derived: sum of 4 quarters · filed 2025-11-06
2024-06-30$1.43M
10-Q · filed 2025-08-07
$2.84M
derived: sum of 2 quarters · filed 2025-08-07
$3.85M
derived: sum of 3 quarters · filed 2025-08-07
$4.81M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31$1.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22
$2.43M
derived: sum of 2 quarters · filed 2025-05-22
$3.38M
derived: sum of 3 quarters · filed 2025-05-22
$4.50M
10-K · filed 2025-05-22
2023-12-31$1.01M
10-Q · filed 2025-02-12
$1.97M
derived: sum of 2 quarters · filed 2025-02-12
$3.08M
10-Q · filed 2025-02-12
$4.10M
derived: sum of 4 quarters · filed 2025-02-12
2023-09-30$955.00K
10-Q · filed 2024-11-12
$2.07M
10-Q · filed 2024-11-12
$3.09M
derived: sum of 3 quarters · filed 2024-11-12
$4.03M
derived: sum of 4 quarters · filed 2024-11-12
2023-06-30$1.11M
10-Q · filed 2024-08-08
$2.14M
derived: sum of 2 quarters · filed 2024-08-08
$3.08M
derived: sum of 3 quarters · filed 2024-08-08
$3.08M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$1.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16
$1.96M
derived: sum of 2 quarters · filed 2024-05-16
$1.96M
derived: sum of 3 quarters · filed 2024-05-16
$1.96M
10-K · filed 2024-05-16
2022-12-31$941.00K
10-Q · filed 2024-02-08
$941.00K
derived: sum of 2 quarters · filed 2024-02-08
$941.00K
10-Q · filed 2024-02-08
$941.00K
derived: sum of 4 quarters · filed 2024-02-08
2022-09-30$0.00
10-Q · filed 2023-11-07
$0.00
10-Q · filed 2023-11-07
$0.00
derived: sum of 3 quarters · filed 2023-11-07
$0.00
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30$0.00
10-Q · filed 2023-08-03
$0.00
derived: sum of 2 quarters · filed 2023-08-03
$0.00
derived: sum of 3 quarters · filed 2023-08-03
$0.00
derived: sum of 4 quarters · filed 2023-08-03
2022-03-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18
$0.00
derived: sum of 2 quarters · filed 2023-05-18
$0.00
derived: sum of 3 quarters · filed 2023-05-18
$0.00
10-K · filed 2023-05-18
2021-12-31$0.00
10-Q · filed 2023-02-09
$0.00
derived: sum of 2 quarters · filed 2023-02-09
$0.00
10-Q · filed 2023-02-09
$1.00K
derived: sum of 4 quarters · filed 2023-02-09
2021-09-30$0.00
10-Q · filed 2021-11-04
$0.00
10-Q · filed 2021-11-04
$1.00K
derived: sum of 3 quarters · filed 2022-05-19
$248.00K
derived: sum of 4 quarters · filed 2022-05-19
2021-06-30$0.00
10-Q · filed 2021-08-06
$1.00K
derived: sum of 2 quarters · filed 2022-05-19
$248.00K
derived: sum of 3 quarters · filed 2022-05-19
$534.00K
derived: sum of 4 quarters · filed 2022-05-19
2021-03-31$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19
$248.00K
derived: sum of 2 quarters · filed 2022-05-19
$534.00K
derived: sum of 3 quarters · filed 2022-05-19
$818.00K
10-K · filed 2022-05-19
2020-12-31$247.00K
10-Q · filed 2022-02-03
$533.00K
derived: sum of 2 quarters · filed 2022-02-03
$817.00K
10-Q · filed 2022-02-03
2020-09-30$286.00K
10-Q · filed 2021-11-04
$570.00K
10-Q · filed 2021-11-04
2020-06-30$284.00K
10-Q · filed 2021-08-06
2020-03-31$734.00K
10-K · filed 2021-05-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B